CurrentUnitedHealthcarePolicy CSNCT0604.07

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for North Carolina Only)

Policy governing coverage of multiplex nucleic acid (PCR) panels for gastrointestinal pathogens for members in North Carolina; describes indications considered medically necessary and those considered not medically necessary for UnitedHealthcare.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for North Carolina Only)

Policy CodePolicy CSNCT0604.07

Change TypeNo material change

Effective DateMay 1, 2026

Next Review Date

Key ActionOrder multiplex GI PCR panels only when guideline-based clinical criteria are met and document those findings in the medical record to support coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3CPT procedure codes listed

up to 25maximum panel targets

7 daysdiarrhea duration threshold

North Carolinajurisdiction

Coverage Criteria for Multiplex Gastrointestinal PCR Panels

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial evaluation coverage criteria

Covered when ANY one of the following clinical situations is present and testing is performed as part of an evaluation that includes blood cultures (for the first group):

Diarrhea duration: Diarrhea for more than 7 daysduration >7 days

[[chunk 3]]

Diarrhea with severe or concerning features: Diarrhea with at least one of: fever; bloody or mucoid stools; severe abdominal cramping or tenderness; signs of sepsissymptom presence

[[chunk 3]]

Suspected enteric fever with exposure history: Suspected enteric fever (typhoid, paratyphoid) in an individual with recent travel to an endemic region or who consumed food prepared by someone with recent endemic exposuretravel/exposure history

[[chunk 3]]

Persistent diarrhea / immunocompromised coverage criteria

Covered when evaluating persistent diarrhea (multiplex PCR panels) in presence of either of the following:

At risk for C. difficile with qualifying features: At risk for Clostridium difficile colitis AND one of: diarrhea for more than 7 days; diarrhea with at least one of fever, bloody or mucoid stools, severe abdominal cramping or tenderness; signs of sepsiscombination risk + features

[[chunk 3]]

Immunosuppressed individuals: On immunosuppressive medications (post-organ transplant or for autoimmune disease) OR other immunosuppressive condition when other stool diagnostic studies have failed to yield a pathogenic organismimmunosuppression

[[chunk 3]]

Guideline-based indications for testing

Covered when ALL of the following guideline-based indications are met

IDSA/ACG indications: Specimen testing is for individuals presenting with moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent (>7 days), or immunocompromised diarrhea where identification of a pathogen may alter managementclinical features per guideline

IDSA and ACG recommend testing under these circumstances; viral panels have limited utility except in immunocompromised patients

Salmonella parallel culture

Additional requirement for Salmonella when molecular testing is performed

Salmonella culture parallelism: When PCR-based assays are used for Salmonella detection, enrichment culture should be performed in parallel to maximize sensitivity and provide isolates for public health and susceptibility testingparallel culture

Hapuarachchi et al. found enrichment culture more sensitive than BD MAX PCR; GPP has propensity for discordance with culture for Salmonella

Multiplex PCR panel testing for gastrointestinal pathogens for indications other than those listed as medically necessary is considered unproven and not medically necessary. The policy specifies coverage only for defined clinical situations (e.g., diarrhea >7 days; diarrhea with fever, bloody/mucoid stools, severe abdominal cramping or signs of sepsis; suspected enteric fever with recent travel/exposure; and evaluation of persistent diarrhea in patients at risk for C. difficile or who are immunosuppressed). Testing outside those scenarios lacks sufficient evidence of efficacy and is not covered.

Routine use of multiplex gastrointestinal pathogen panels in low-yield populations (for example, patients with acute, self-limited, noninflammatory diarrhea without risk factors) is discouraged. Evidence shows multiplex panels detect more pathogen-positive results than conventional methods but can produce additional findings of uncertain clinical importance, increasing false positives and leading to unnecessary treatment or interventions.

Use of multiplex PCR panels for gastrointestinal pathogens is covered only for the specific medically necessary indications listed in this policy. Requests for testing for indications not enumerated (for example, routine screening or evaluation of uncomplicated short-duration diarrheas that do not meet the policy criteria) are considered not medically necessary and may be denied.

Testing patients who do not meet the clinical criteria outlined in this policy — such as individuals with noninflammatory, short-duration uncomplicated diarrhea without fever, bloody stools, severe abdominal pain, signs of sepsis, or immunocompromise — is of low clinical yield. Retrospective and systematic evidence indicates that applying guideline-based criteria (e.g., IDSA recommendations) reduces unnecessary testing without significantly decreasing clinical yield, so routine multiplex panel testing in these scenarios is not supported.

Indications Considered Medically Necessary

Multiplex PCR panel coverage (3–25 targets) — selected covered scenarios

Covered indications (summary — multiplex PCR panels, 3–25 targets):

Duration or severe features: Diarrhea >7 days; OR diarrhea with fever, bloody/mucoid stools, severe abdominal cramping/tenderness, or signs of sepsisduration >7 days or symptom presence

Testing described for multiplex panels (3-25 targets) and described as performed as part of an evaluation that includes blood cultures

Suspected enteric fever with relevant travel or exposure historytravel/exposure history

[[chunk 3]]

Persistent diarrhea with risk factors: Persistent diarrhea in individuals at risk for C. difficile or who are immunosuppressed after other stool studies are non-diagnosticpersistent + risk/immunosuppression

[[chunk 3]]

Guideline-based contexts for multiplex panel use

Guideline recommendations supporting use of multiplex panels in these clinical contexts:

Moderate-to-severe or complicated presentations: Moderate-to-severe, bloody, or febrile diarrhea; nosocomial diarrhea; or persistent diarrhea (>7 days)clinical severity/duration

IDSA recommends testing in these contexts; culture-independent multiplex tests are recommended for bacterial pathogens

Immunocompromised hosts: Immunocompromised patients — viral panels may be useful; testing indicated when pathogen identification would affect managementimmunocompromise

IDSA notes limited utility of viral panels except in immunocompromised patients

Coding and Panel Target Counts

Referenced CPT CodesCPT

87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Panel target count (by CPT group)

CPT panel target group3-5 targets (CPT 87505); 6-11 targets (CPT 87506); 12-25 targets (CPT 87507)

CPT guidance sourceCPT descriptions list examples of organisms and group targets tied to codes 87505-87507

Maximum targets referenced in evidenceUp to 25 targets (discussed in Allplex 25-pathogen assay and related clinical evidence)

Provider Responsibilities and Ordering Guidance

Prior Authorization

Coverage tied to clinical criteria

Multiplex gastrointestinal (GI) PCR panel testing (CPT 87505-87507) is covered only when the clinical criteria listed in this policy are met. Providers should order multiplex GI panels in accordance with guideline-recommended indications (for example: moderate-to-severe disease, bloody or febrile diarrhea, persistent symptoms, or immunocompromised status). When testing is indicated, culture-independent molecular methods are the preferred modality for bacterial pathogen detection in individuals meeting criteria.

Affected codes: CPT 87505-87507

Note

Parallel culture recommended for Salmonella

When PCR-based testing is used for enteric pathogens, consider performing parallel enrichment culture for Salmonella. Enrichment culture may be more sensitive than some PCR assays and provides isolates needed for public health surveillance and antimicrobial susceptibility testing; parallel culture can reduce false negatives and support confirmatory testing.

Recommended when PCR-based detection of Salmonella is performed: parallel enrichment culture

Documentation Required

Medical record documentation requirements

The patient's medical record must contain documentation that supports medical necessity for multiplex GI panel testing. Documentation should include relevant history, physical examination findings, and rationale that the clinical presentation meets guideline-based indications (e.g., fever, bloody stool, severe or persistent symptoms, immunocompromised status). Records should be legible, maintained in the member’s chart, and made available upon request to support coverage decisions.

Include: pertinent history, exam findings, diagnostic test results, and indication rationale (e.g., fever, bloody/mucoid stools, duration >7 days, immunosuppression)

Denial Risk

Denial risk for unproven indications

Requests for multiplex PCR panel testing for gastrointestinal pathogens for indications other than the medically necessary indications listed in this policy may be denied. Ordering testing outside of guideline-recommended indications (for example, testing for noninflammatory, self-limited diarrhea without fever, bloody stool, persistent symptoms, or immunocompromised status) increases the risk of overuse and denial.

Testing outside IDSA/ACG guideline indications may be denied

Definitions

Multiplex PCR panel — definition

DefinitionMultiplex PCR panel: a nucleic-acid amplification test that detects multiple gastrointestinal pathogens from a single specimen using multiplexed PCR methods

Intended useUsed to identify bacterial, viral, and some parasitic enteropathogens in patients meeting clinical indications (e.g., moderate-to-severe, bloody, febrile, persistent diarrhea)

LimitationsPanel scope is restricted to included organisms; detection may identify nucleic acid from viable or nonviable organisms and may not distinguish colonization from infection

Culture-independent multiplex molecular tests (GPP)

DefinitionCulture-independent multiplex molecular tests (GPP): NAAT-based panels that detect multiple enteric pathogens simultaneously from a single specimen without the need for culture

Performance characteristicsReported to have greater sensitivity and faster turnaround time than culture-based methods; can detect mixed infections and organisms not routinely cultured

Clinical considerationsMay not distinguish viable from nonviable organisms; viral targets often have limited clinical impact except in immunocompromised patients; panel size and interpretation can affect clinical utility

OpenPayer

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for North Carolina Only)

Coverage Criteria for Multiplex Gastrointestinal PCR Panels

Indications Considered Medically Necessary

Coding and Panel Target Counts

Provider Responsibilities and Ordering Guidance

Ordering and Documentation Requirements

Frequency Limits and Re-testing

Not Medically Necessary / Not Covered

Definitions

Background and Evidence Summary